KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Other Gross PP&E Adjustments (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Gross PP&E Adjustments for 15 consecutive years, with $32.2 million as the latest value for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 26.03% to $32.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.2 million through Dec 2025, up 26.03% year-over-year, with the annual reading at $32.2 million for FY2025, 26.03% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $32.2 million at Halozyme Therapeutics, up from $23.0 million in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was $37.8 million in Q3 2022, with the low at -$18.4 million in Q1 2025.
  • Average Other Gross PP&E Adjustments over 5 years is $18.0 million, with a median of $16.7 million recorded in 2021.
  • The sharpest move saw Other Gross PP&E Adjustments skyrocketed 174.34% in 2023, then plummeted 174.07% in 2025.
  • Over 5 years, Other Gross PP&E Adjustments stood at $16.0 million in 2021, then tumbled by 67.55% to $5.2 million in 2022, then surged by 174.34% to $14.2 million in 2023, then soared by 79.55% to $25.6 million in 2024, then increased by 26.03% to $32.2 million in 2025.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at $32.2 million, $23.0 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.